Skip to main content

Rakovina Therapeutics Inc.

Category: AI in Healthcare

A biopharmaceutical company developing innovative, AI-powered cancer treatments targeting the DNA-damage response (DDR). Rakovina Therapeutics Inc. was founded in 2020. The company is led by Jeffrey Bacha. Based in Vancouver, Canada. Team size: 1-10. Total funding raised: $4.9 Million. Latest round: Private Placement. Key investors include N/A.

Founded
2020
Headquarters
Vancouver, Canada
Team size
1-10
Total funding
$4.9 Million

Value proposition

To significantly shorten drug discovery timelines and increase the precision of cancer therapies by using proprietary AI platforms.

Products and solutions

A pipeline of small-molecule drug candidates targeting the DNA-damage response (DDR) pathway., Lead candidates developed using their AI-powered drug discovery engine.

Unique value

Employs a unique combination of AI-powered drug discovery and deep expertise in DNA-damage response (DDR) to develop next-generation cancer therapies.

Target customer

Cancer patients who can benefit from targeted DNA-damage response therapies.

Industries served

Biotechnology, Pharmaceuticals, Oncology

Technology advantage

Proprietary AI platforms (in collaboration with Variational AI) that compress drug discovery timelines from years to months, potentially reducing R&D costs and accelerating time-to-market.

How they differentiate

Rakovina Therapeutics focuses on developing new cancer treatments based on novel DNA-damage response (DDR) technologies. The company leverages its proprietary AI-powered drug discovery platform, Deep-Screen, to identify and develop drug candidates. Its joint venture with NanoPalm for novel lipid nanoparticle delivery of its AI-discovered therapies is also a key differentiator.

Main competitors

Exscientia, Insilico Medicine, Recursion Pharmaceuticals

Key partnerships

Joint Venture with NanoPalm for AI-driven oncology therapies., Research collaboration with Variational AI Inc. to identify and develop novel small-molecule therapies.

Notable customers

Joint venture with NanoPalm Ltd. to develop and commercialize Rakovina's kt-3000 series, beginning with KT-3283, a dual PARP-HDAC inhibitor.

Major milestones

Successfully closed an oversubscribed private placement of $4.9 million., Entered into a joint venture with NanoPalm Ltd. to advance its AI-discovered oncology therapies using novel lipid nanoparticle delivery technologies., Established a pipeline of drug candidates based on its proprietary Deep-Screen AI platform.

Growth metrics

Publicly traded on the TSX Venture Exchange (TSXV: RKV).

Market positioning

Rakovina is a preclinical-stage biopharmaceutical company, publicly traded on the TSX Venture Exchange (TSXV: RKV). It is positioned as a niche player focusing on the intersection of AI-driven drug discovery and DNA-damage response mechanisms in oncology.

Geographic focus

The company is headquartered in Vancouver, Canada, with a strategic focus on accelerating US-focused growth and expanding its presence in the United States market.

Patents and IP

Proprietary drug candidates and technology platforms. Specific patent details are not publicly listed.

About Jeffrey Bacha

Mr. Bacha has been involved in pharmaceutical research for more than 25 years as a member of the executive leadership team for multiple companies. He is the founder and Executive Chairman of Rakovina Therapeutics. Prior to founding Rakovina, Mr. Bacha co-founded Kintara Therapeutics (formerly DelMar Pharmaceuticals) with Dr. Dennis Brown, serving as Chairman and CEO. He has also held leadership roles at Inimex Pharmaceuticals, XBiotech, and Clera.

Official website: